Ovarian Cancer Clinical Trials in Sioux Falls, South Dakota

9 studies are recruiting for ovarian cancer in Sioux Falls, South Dakota right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

   This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Sanford Health, Sioux Falls, South Dakota

   Locations

   9 in total

   Run by

   Imunon

   See if you can join NCT06915025 on ClinicalTrials.gov

2. Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

   The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Sanford Cancer Center-Sioux Falls, Sioux Falls, South Dakota

   Locations

   192 in total

   Run by

   Incyte Corporation

   See if you can join NCT07214779 on ClinicalTrials.gov

3. Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

   This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other ant…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Avera Cancer Institute Sioux Falls, Sioux Falls, South Dakota

   Locations

   56 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT06787612 on ClinicalTrials.gov

4. A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

   Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine with carboplatin, or bevacizumab (Bev), or bev alone in part…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Avera Cancer Institute - Sioux Falls /ID# 278627, Sioux Falls, South Dakota

   Locations

   83 in total

   Run by

   AbbVie

   See if you can join NCT07059845 on ClinicalTrials.gov

5. A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

   This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein expression.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Site 0112, Sioux Falls, South Dakota

   Locations

   59 in total

   Run by

   K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

   See if you can join NCT07546500 on ClinicalTrials.gov

6. Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

   This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry [IHC] 3+/2+/1+) advanced high-g…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Avera Medical Group Gynecologic, Sioux Falls, South Dakota

   Locations

   208 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06819007 on ClinicalTrials.gov

7. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

   A Study of Emi-Le in Participants with Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Avera Cancer Institute, Sioux Falls, South Dakota

   Locations

   26 in total

   Run by

   Day One Biopharmaceuticals, Inc.

   See if you can join NCT05377996 on ClinicalTrials.gov

8. A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

   The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701. The main questions the trial aims to answer are: * Does COM701, wh…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Avera Cancer Institute, Sioux Falls, South Dakota

   Locations

   28 in total

   Run by

   Compugen Ltd

   See if you can join NCT06888921 on ClinicalTrials.gov

9. Avera Cancer Sequencing and Analytics Protocol (ASAP)

   The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare system. Through comprehensive genomic profiling, investigators aim to identify the underlying genomic drivers of premalignant …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Avera Cancer Institute, Sioux Falls, South Dakota

   Locations

   6 in total

   Run by

   Avera McKennan Hospital & University Health Center

   See if you can join NCT05142033 on ClinicalTrials.gov